Biomarkers of treatment effect in a phase II trial of velimogene aliplasmid in patients with metastatic melanoma.

Mary K. Wloch,Dmitri D. Kharkevitch,Alice Chu,John Schulte,Larry R Smith,Richard T. Kenney,Alain Rolland

Biomarkers of treatment effect in a phase II trial of velimogene aliplasmid in patients with metastatic melanoma.

2012

Mary K. Wloch
Dmitri D. Kharkevitch
Alice Chu
John Schulte
Larry R Smith
Richard T. Kenney
Alain Rolland

e19058 Background: Velimogene aliplasmid (Allovectin, A) is a plasmid-based immunotherapeutic that encodes human leukocyte antigen-B7 and β-2 microglobulin. A is designed to induce allogeneic and t...

Keywords:

Pathology
metastatic melanoma
Biomarker (medicine)
treatment effect
Internal medicine
Oncology
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations